Product Description
MK-2748 is hepatitis C Virus NS3/4a Protease Inhibitor patented by pharmaceutical company Merck & Co Co for the treatment of hepatitis C virus infection. (Sourced from: https://drugs.ncats.io/drug/7YM030A71C)
Mechanisms of Action: HCV-NS3/4A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hepatitis A|Hepatitis C
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01593735 |
MK-2748-002 AM1 | P1 |
Completed |
Hepatitis C|Hepatitis A |
2013-02-01 |
2022-05-04 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|